PRELUDE THERAPEUTICS INC (PRLD)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
What PRELUDE THERAPEUTICS INC does
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates using its proprietary understanding of protein function and disease biology. The company is pursuing multiple therapeutic programs across different disease areas, with a focus on first-in-class and best-in-class opportunities. As of Q1 2026, Prelude reported its first revenue of $4.58 million, indicating progress toward commercialization or partnership milestones. The company remains unprofitable with significant R&D spending as it advances its pipeline through clinical development and regulatory approval pathways.
Themes: oncology / cancer research, precision medicine, clinical-stage drug development
Fundamentals
- Price$6.63 as of 2026-08-21 close
- Market cap$529M as of 2026-08-21
- 1-year return+502.7% 2025-08-21 close $1.10 → 2026-08-21 close $6.63
- P/En/a negative earnings
- Net margin-278.5% as of 2026-08-24
- ROE-74.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+41.0% as of 2026-08-24
- Beta0.94 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How PRLD compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PRELUDE THERAPEUTICS INC looks technically
PRELUDE THERAPEUTICS INC (PRLD) is trading 98.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 236 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 2.7% below its 52-week high (its highest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 98.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +98.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.73 | $4.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.34 | $3.34 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 52 calendar days ago — the swings before that are what the structure reading is measured on | 52 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 236 trading days ago — a "golden cross", a bullish long-term signal | 236 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 33.0 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70) | 75.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($4.37 to $6.82) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 92.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.82 | $6.82 |
|---|---|---|
| From the 52-week high | it is 2.7% below its 52-week high (its highest price of the past year) | -2.7% |
| Above the 52-week low | it is 715.5% above its 52-week low (its lowest price of the past year) | +715.5% |
| Below the 52-week high | it is 2.7% below its highest point of the past year | 2.7% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $76.67 (set on 2021-02-22) | $76.67 |
| Given back of the 52-week move | over the past year its closes ranged ($0.87 to $6.63), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.89 to $3.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 91.4% below its all-time high | -91.3% |
| Nearest price level | it is trading 16.5% above a support level at $5.54 — a price it turned at twice since 2024-09-10, most recently on 2026-04-15. Since 2024-08-21 it has 6 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -16.5% |
| All-time low | its lowest closing price on record is $0.61 (set on 2025-04-08) | $0.61 |
| Above the all-time low | it is 986.9% above its all-time low | +986.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4479 between its high and its low — about 6.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4479 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.76 and $6.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.76 – $5.15 – $6.54 |
| Typical daily range (% of price) | its price moves about 6.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.8% |
| Stretch from the 200-day average | it is trading 7.4 daily ranges above its 200-day average price (98.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 17.0% above the previous close 18 sessions ago and has not traded back through the level it left behind at 3.89 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +17.0% |
| Gap filled | a 2.5% gap up opened on 2026-08-11 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 6 sessions in a row, a +23.69% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 6 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 61.8 percentage points (the stock gained 64.1% while the market gained 2.3%) | +61.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 50.0 percentage points (the stock gained 53.1% while the market gained 3.1%) | +50.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 127.4 percentage points (the stock gained 138.5% while the market gained 11.1%) | +127.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 482.2 percentage points (the stock gained 502.7% while the market gained 20.5%) | +482.3% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 41% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.3% of the share price. | +41.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 65% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.03 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +64.6% |
|---|
Price levels it has turned at before
PRLD last closed at $6.63 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.54 | Support | 16.5% below the last close | turned there twice · 2024-09-10 to 2026-04-15 |
| $3.98 | Support | 40.0% below the last close | turned there twice · 2026-03-11 to 2026-05-19 |
| $3.00 | Support | 54.8% below the last close | turned there twice · 2025-12-29 to 2026-01-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$8.00 range $6.00 – $10.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRLD
- Consensus EPS estimate-$0.185 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant operating losses and expectation of continued losses for the foreseeable future.","Dependence on early-stage clinical trial success and uncertainty regarding regulatory approval.","Requirement for substantial additional capital to fund ongoing research and development operations."]
What changed in the latest 10-Q
AI-assisted comparison of PRLD's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K filed March 10, 2026 (newer filing) vs. March 10, 2025 (older filing)
- Reference to 2025 Annual Report on Form 10-K (newer) vs. 2024 Annual Report on Form 10-K (older)
- Statement about 'advancing a pipeline of novel precision oncology development candidates, alone and with partners' (newer)
- Addition of full name spelling: 'Janus Kinase 2' with abbreviation 'JAK2' in parentheses (newer)
- Addition of full name spelling: 'calreticulin' with abbreviation 'CALR' in parentheses (newer)
- New paragraph about PRT12396 lead candidate: IND clearance announcement (February 2026), Phase 1 study initiation, enrollment commencement in PV and MF patients, and study details (newer)
- Revised Incyte agreement language: 'entered into' changed to past tense completion; explicit naming of program as 'JAK2V617F inhibitor program' (newer)
- Addition of specific details about Incyte option agreement: description as 'the Exclusive Option Agreement' and reference to 'the Program' (newer)
- Statement that company 'expect[s] to advance the JAK2V617F program to pre-defined milestones' (newer)
- New paragraph about KAT6A degraders program referencing PRT13722 as lead development candidate and presentation at American [meeting details cut off] (newer)
- Removed:
- Statement about 'creating a wholly-owned, internally developed pipeline' (older)
- Phrase 'developing therapies that target primary and secondary resistance mechanisms' replaced with reference to 'advances in new therapeutic modalities such as targeted protein degradation' (older wording removed)
- Older phrasing: 'have entered into an exclusive option agreement' changed from future-oriented language (older)
- Reference to 'JAK2V617F JH2 inhibitor program' (older terminology)
- Statement about KAT6A development candidate selection and mid-2026 IND filing timeline (older)
- Statement about 'recently presented preclinical data supporting this hypothesis at the American Association for Cancer Research Annual Meeting 2025' (older)
- Entire paragraph about June 2025 European Hematology Association presentation on mCALR discovery efforts and CALRxSMARCA2/4 degrader antibody conjugate (older)
- Sentence fragment beginning 'Drawing on our expertise in targeted protein degradation...' (older, text cut off)
- Reworded:
- 'the effect of continued federal government shutdown' changed to 'the effect of continued federal government shutdown' (no substantive change, but older used 'effects of a continued')
- Acronym formatting: 'HSC' now appears in parentheses after 'hematopoietic stem cells' in both versions but newer version formats more consistently
- Program description: older used 'JAK2V617F JH2 inhibitor program' while newer uses 'mutative selective JAK2V617F inhibitor program' (changed terminology)
- Language shift from 'have entered into' (older) to 'entered into' (newer) for Incyte agreement timing
- Addition of phrase 'by harnessing advances in new therapeutic modalities such as targeted protein degradation' (newer strategic focus language) replacing older phrase about 'targeting primary and secondary resistance mechanisms'
- Notes:
- Older filing text appears truncated at end ('Drawing on our expertise in targeted protein degradation, we have discovered and optimized a series of proprietary degrader payloads for use i'), preventing full comparison of that section
- Newer filing text also appears truncated ('We presented preclinical data from our lead development candidate, PRT13722, at the American'), preventing full comparison of that section
Risk Factors
- Added:
- Newer filing (2026-05-12) includes deferred revenue line item in balance sheet liabilities ($30,952 current, $0 non-current as of March 31, 2026)
- Newer filing (2026-05-12) reports revenue of $4,580 thousand for three months ended March 31, 2026
- Newer filing (2026-05-12) shows 'Right-of-use asset' line item in balance sheet ($26,778 thousand as of March 31, 2026) replacing 'Operating lease right-of-use asset'
- Newer filing (2026-05-12) shows non-voting common stock shares authorized increased to 112,850,259 (same shares issued and outstanding)
- Newer filing (2026-05-12) balance sheet dated March 31, 2026 compared to December 31, 2025 in prior quarter format
- Newer filing (2026-05-12) cash flows statement shows 'Payment of offering costs' ($294 thousand) for three months ended March 31, 2026
- Removed:
- Older filing (2025-11-12) included 'Finance lease liability' line item ($208 thousand current as of December 31, 2024) not present in newer filing
- Older filing (2025-11-12) labeled line item as 'Operating lease right-of-use asset' rather than 'Right-of-use asset'
- Older filing (2025-11-12) reported nine-month period data alongside quarterly data in statements of operations; newer filing reports only quarterly data
- Older filing (2025-11-12) non-voting common stock authorized shares listed as 112,850,259 and 12,850,259 at two different dates; newer filing shows consistent 112,850,259
- Reworded:
- Balance sheet comparison dates changed from 'September 30, 2025 and December 31, 2024' (older filing 2025-11-12) to 'March 31, 2026 and December 31, 2025' (newer filing 2026-05-12)
- Line item 'Other assets' ($110 thousand in older filing) relabeled as 'Prepaid expenses and other non-current assets' ($314 thousand in newer filing)
- Cash flows statement period changed from 'Nine months ended September 30' (older filing 2025-11-12) to 'Three months ended March 31' (newer filing 2026-05-12)
- Notes:
- The older filing appears truncated mid-sentence in the provided text ('Prepaid expenses and other c...'), potentially limiting complete assessment of all changes
- Financial data comparison is between different reporting periods (Q1 2026 vs. Q3 2025 and FY 2024), so period-over-period changes reflect both timing and operational differences
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days4 buys ($25M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-04-21. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PRLD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PRLD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 865,704
- Reported value $2,960,708
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PRLD had 3,669,933 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PRLD had 4.60% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.31 days to cover at the same settlement.
- Reported short interest (shares) 3,669,933
- Short interest (% of shares outstanding) 4.60%
- Prior settlement (shares) 3,286,206
- Reported change 11.68%
- Days to cover (reported) 9.31
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Blueprint Medicines (BPMC)
- Gilead Sciences (GILD)
- Novartis (NVS)
- AstraZeneca (AZN)
- Merck & Co. (MRK)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRLD vs…
PRELUDE THERAPEUTICS INC is found in…
PRLD ranks in…
Frequently asked questions
What does PRELUDE THERAPEUTICS INC (PRLD) do?
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates using its proprietary understanding of protein function and disease biology. The company is pursuing multiple therapeutic programs across different disease areas, with a focus on first-in-class and best-in-class opportunities. As of Q1 2026, Prelude reported its first revenue of $4.58 million, indicating progress toward commercialization or partnership milestones.
What sector is PRELUDE THERAPEUTICS INC (PRLD) in?
PRELUDE THERAPEUTICS INC (PRLD) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are PRELUDE THERAPEUTICS INC's (PRLD) competitors?
Notable peers of PRELUDE THERAPEUTICS INC (PRLD) include Blueprint Medicines, Gilead Sciences, Novartis, AstraZeneca and Merck & Co.. This peer set is informational only — not financial advice.
Is PRELUDE THERAPEUTICS INC (PRLD) overbought or oversold right now?
PRELUDE THERAPEUTICS INC (PRLD) is currently in overbought territory (its 14-day RSI is 75, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRLD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.